Developing personalized adjuvant treatment strategies for early-stage breast cancer: Addressing a clear unmet medical need
Inbiomotion focuses on providing a unique companion diagnostic solution, to address an urgent and unmet medical need in the personalized adjuvant treatment of early-stage breast cancer.
Founded in 2010 by Prof. Roger Gomis, Inbiomotion is a spin-off of IRB Barcelona and ICREA research institutions.
Our unique diagnostic assay is based on a highly selective, single-gene biomarker, of the MAF gene. The MAF test has the potential to identify early-stage breast cancer patients who will benefit from bisphosphonate adjuvant treatment, with the aim to improve their overall and disease-free survival, while excluding patients who will not benefit or can be harmed. It can further predict, at an early stage, a patient's risk of metastases relapse from primary tumors.
Inbiomotion has discovered and validated MAF, a unique biomarker predictive of clinical benefit of adjuvant bisphosphonates in early breast cancer patients.
MAF allows selection of early-stage breast cancer patients benefiting from adjuvant bisphosphonate treatment using Inbiomotion proprietary diagnostic assay MAF Test®:
- MAF negative patients will be eligible for Clodronate adjuvant treatment in early breast cancer, including non-post-menopausal patients currently not recommend in guidelines.
- MAF positive patients will be excluded from Clodronate adjuvant treatment, including post-menopausal patients who do not benefit or may be harmed.
Selection of MAF negative patients for treatment with bisphosphonates could have a deep impact on the outcome of early breast cancer patients, reducing in a 35% the number of deaths of patients treated with standard chemo/hormonal therapies.